Johannes Jacob Piete Kastelein Sells 45,481 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the transaction, the insider directly owned 53,500 shares of the company’s stock, valued at approximately $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00.

NewAmsterdam Pharma Stock Down 2.8%

Shares of NewAmsterdam Pharma stock opened at $35.01 on Thursday. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The company has a market capitalization of $3.97 billion, a P/E ratio of -20.24 and a beta of 0.06. The company has a 50 day moving average of $34.04 and a 200 day moving average of $32.87.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. As a group, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the last quarter. Mather Group LLC. purchased a new position in NewAmsterdam Pharma during the 3rd quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in NewAmsterdam Pharma in the third quarter valued at $30,000. Wells Fargo & Company MN increased its stake in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the period. Finally, Navalign LLC purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $46,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NAMS has been the subject of several analyst reports. The Goldman Sachs Group upped their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Needham & Company LLC boosted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Royal Bank Of Canada raised their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.